Yellow Dye 6 vs Butylated Hydroxyanisole: which is worse?

What is Yellow Dye 6?

Yellow Dye 6 (Sunset Yellow FCF) is a synthetic orange-yellow azo dye derived from petroleum. It produces a bright orange-yellow color and is structurally similar to Yellow 5 but produces a more orange shade. Its chemical formula is C16H10N2Na2O7S2.

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum (see also bha entry). It is a mixture of 2-BHA and 3-BHA isomers, used to prevent oxidative rancidity in fats, oils, and fat-containing foods. Chemical formula C11H16O2.

Documented risks

Yellow Dye 6: Yellow Dye 6 was included in the 2007 Lancet study (McCann et al.), which found that a mixture of six dyes including Yellow 6 and sodium benzoate significantly increased hyperactivity in children. EFSA confirmed the effect warranted mandatory warning labels in the EU. EFSA's 2009 re-evaluation examined animal carcinogenicity data and found some studies showing adrenal tumors in male mice at high doses. EFSA set an ADI of 2.5 mg/kg body weight — lower than Yellow 5's ADI of 7.5 mg/kg, reflecting greater concern. The review noted limitations in the available data. Impurity concerns: commercial batches of Yellow 6 have been found to contain aromatic amine impurities including benzidine and 4-aminobiphenyl — both IARC Group 1 human carcinogens. A 1992 CSPI analysis documented these impurities, citing them as reason for concern. A 2007 study in Toxicological Sciences found Yellow 6 altered zinc and iron biomarker levels in rat blood at high doses, raising mineral metabolism concerns. Human relevance at typical exposure is unclear. Hypersensitivity reactions including urticaria, rhinitis, and contact dermatitis are documented. Cross-reactivity with aspirin is reported similarly to Yellow 5. In April 2025, the FDA announced plans to phase out Yellow 6 with other petroleum-based dyes.

Butylated Hydroxyanisole: IARC classifies BHA as Group 2B (possible human carcinogen) based on forestomach tumor studies in rodents at high doses. The NTP lists it as 'reasonably anticipated to be a human carcinogen.' EFSA's 2012 review found endocrine-disrupting potential. Japan banned it for food use. The FDA permits it at 0.02% of fat content. Concerns about estrogen-receptor interaction have been documented in animal studies. Contact dermatitis from cosmetic use is reported.